TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33527492

Group type: EXPERIMENTAL
Intervention: Length of stay (LOS) analysis among diseases using a new conditional network construction approach.
Number of subjects: 100000
Study: 33053283

Group type: EXPERIMENTAL
Intervention: Upadacitinib (15 mg once daily)
Number of subjects: 612

Group type: COMPARATOR
Intervention: Abatacept (intravenous)
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Upadacitinib
Number of subjects: 612

Group type: COMPARATOR
Intervention: Abatacept
Number of subjects: 612
Study: 35714312

Group type: EXPERIMENTAL
Intervention: Enasidenib 100 mg/day
Number of subjects: 319

Group type: COMPARATOR
Intervention: Conventional care regimens (CCR)
Number of subjects: 319
Study: 34648003

Group type: EXPERIMENTAL
Intervention: Customized preformed foot orthoses
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard flat innersole (sham)
Number of subjects: 66
Study: 34857029

Group type: EXPERIMENTAL
Intervention: NIDUS-family intervention with usual care (n = 199)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Usual care alone (n = 98)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: NIDUS-family intervention with usual care
Number of subjects: 297

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 297
Study: 35353097

Group type: EXPERIMENTAL
Intervention: CPS morsels (Test I; n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CPS+PRF (Test II; n = 10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups (CPS, CPS+PRF, Control)
Number of subjects: 30
Study: 33641816

Group type: EXPERIMENTAL
Intervention: Hyrax
Number of subjects: 0

Group type: COMPARATOR
Intervention: Damon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 0
Study: 35472588

Group type: EXPERIMENTAL
Intervention: Non-intubated group (opioid-sparing strategies)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Intubated group (double-lumen tube intubation)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Non-intubated group
Number of subjects: 217

Group type: COMPARATOR
Intervention: Intubated group
Number of subjects: 217
Study: 34653526

Group type: EXPERIMENTAL
Intervention: Short-course preoperative radiotherapy (5 × 5 Gy) followed by surgery 7-10 days after irradiation
Number of subjects: 154

Group type: COMPARATOR
Intervention: Long interval surgery (surgery 4-5 weeks after irradiation)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Patients with downstaging after radiotherapy
Number of subjects: 154
Study: 34369683

Group type: EXPERIMENTAL
Intervention: Tiaoren tongdu acupuncture method
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (basic treatment with conventional medication)
Number of subjects: 54
Study: 32193052

Group type: EXPERIMENTAL
Intervention: Individualized exercise-training (IET) program with educational sessions
Number of subjects: 64

Group type: COMPARATOR
Intervention: Educational sessions alone (Control Group)
Number of subjects: 64
Study: 34864617

Group type: EXPERIMENTAL
Intervention: n-3 long chain polyunsaturated fatty acid (LCPUFA) supplementation
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Whole blood total n-3 fatty acids
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Plasma total n-3 fatty acids
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: n-3 LCPUFA supplementation
Number of subjects: 457
Study: 32404001

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 87

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Economic evaluation
Number of subjects: 87
Study: 33528288

Group type: EXPERIMENTAL
Intervention: Make Ready Model (MRM)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard Cleaning Model (SCM)
Number of subjects: 68
Study: 34569327

Group type: EXPERIMENTAL
Intervention: Use of mobile applications for health and parenting information
Number of subjects: 1155

Group type: EXPERIMENTAL
Intervention: Development of evidence-based and culturally-adapted mobile apps
Number of subjects: 1155
Study: 32332265

Group type: EXPERIMENTAL
Intervention: Fibreoptic-guided group
Number of subjects: 123

Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 123
Study: 35813848

Group type: EXPERIMENTAL
Intervention: Low energy availability (EA) reduced by 25% and 75%
Number of subjects: 0
Study: 33120762

Group type: EXPERIMENTAL
Intervention: Modified Shenling Baizhu Powder
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 35756420

Group type: EXPERIMENTAL
Intervention: Oxycodone (0.02 mg/kg)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Sufentanil (0.02 µg/kg)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 144
Study: 33962962

Group type: EXPERIMENTAL
Intervention: Intra-articular sprifermin 100 μg every 6 months (q6mo)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Intra-articular sprifermin 100 μg q6mo
Number of subjects: 378

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 378
Study: 33349862

Group type: COMPARATOR
Intervention: Romidepsin (RMD) 0.5 mg/m2, 2 mg/m2, 5 mg/m2 (single dose)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Romidepsin (RMD) 5 mg/m2 (multi-dose)
Number of subjects: 43
Study: 34749132

Group type: EXPERIMENTAL
Intervention: Very-low-calorie diet (VLCD) with 77 g/day protein for 8 weeks
Number of subjects: 108

Group type: COMPARATOR
Intervention: Very-low-calorie diet (VLCD) with 52 g/day protein for 8 weeks
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both VLCDs
Number of subjects: 108
Study: 35916669

Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic intervention (L. paracasei CNCM I‐1518, L. paracasei CNCM I‐3689, L. rhamnosus CNCM I‐3690, and four yogurt strains)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (without probiotic intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 32616452

Group type: EXPERIMENTAL
Intervention: Family Empowerment Education (My Asthma Therapeutic Education)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study: 32241898

Group type: EXPERIMENTAL
Intervention: 2G-NBI
Number of subjects: 4523

Group type: COMPARATOR
Intervention: WLI
Number of subjects: 4523
Study: 34321133

Group type: EXPERIMENTAL
Intervention: Health harms awareness
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Environmental harms awareness
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Discouragement from health harms
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: General perceptions and demographics
Number of subjects: 544
Study: 33657531

Group type: EXPERIMENTAL
Intervention: CT-EX (30-minute cognitive task followed by a 15-minute high-intensity interval exercise bout)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: CT-CD (30-minute cognitive task performed on a cycling desk)
Number of subjects: 19

Group type: COMPARATOR
Intervention: CON (resting session)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: CT (30-minute cognitive task)
Number of subjects: 19
Study: 33942212

Group type: EXPERIMENTAL
Intervention: 20 mM citrate buffer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mM citrate buffer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 mM citrate buffer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NaCl and propylene glycol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histidine buffers (150 mM, 75 mM, 25 mM, 0 mM NaCl)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histidine buffers containing Arginine‐HCl (0, 50, or 150 mM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histidine buffer at pH 6.5
Number of subjects: 0
Study: 32015415

Group type: EXPERIMENTAL
Intervention: Weight loss intervention (specifics not provided)
Number of subjects: 0
Study: 34911168

Group type: EXPERIMENTAL
Intervention: Non-interruptive alert in the ordering IT-system
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Interruptive alert in the ordering IT-system
Number of subjects: 313

Group type: COMPARATOR
Intervention: Guidelines alone
Number of subjects: 313

Group type: COMPARATOR
Intervention: Guidelines combined with feedback reports
Number of subjects: 313

Group type: COMPARATOR
Intervention: Monthly feedback reports
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Combination of alerts and feedback reports
Number of subjects: 313
Study: 34204017

Group type: EXPERIMENTAL
Intervention: Lingual laser frenectomy using a diode laser (power 7 W)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group with myofunctional and speech therapy
Number of subjects: 32
Study: 36434512

Group type: EXPERIMENTAL
Intervention: Neurexan (Nx4)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34441773

Group type: EXPERIMENTAL
Intervention: Immediate loading protocol using VulkanLoc® abutments after implant emplacement
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional loading protocol with VulkanLoc® abutments connected two months after surgery
Number of subjects: 20
Study: 35298997

Group type: COMPARATOR
Intervention: Emotion regulation task during fMRI scanning in rrMDD patients
Number of subjects: 70

Group type: COMPARATOR
Intervention: Explicit downregulation of negative emotions
Number of subjects: 70

Group type: COMPARATOR
Intervention: Explicit upregulation of positive emotions
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Daily life regulation strategies
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Rumination in rrMDD patients
Number of subjects: 70
Study: 33368969

Group type: EXPERIMENTAL
Intervention: Endoxifen (8 mg daily)
Number of subjects: 116
Study: 32612272

Group type: EXPERIMENTAL
Intervention: Moderate physical activity
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Vigorous physical activity
Number of subjects: 833

Group type: COMPARATOR
Intervention: Light physical activity
Number of subjects: 833
Study: 35688247

Group type: EXPERIMENTAL
Intervention: Lysinibacillus fusiformis strain Lf (ureolytic bacteria)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 35164695

Group type: EXPERIMENTAL
Intervention: Simulation training intervention (IMPETUS-D) for nursing home staff
Number of subjects: 1304

Group type: COMPARATOR
Intervention: Usual training opportunities for nursing home staff (Control)
Number of subjects: 1304
Study: 34726650

Group type: EXPERIMENTAL
Intervention: Text messaging intervention by postpartum nurse navigator (PPNN)
Number of subjects: 43
Study: 32965505

Group type: EXPERIMENTAL
Intervention: Prognostic index model for treatment outcome
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Prognostic index model for post-treatment participation
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Cross-validated prognostic index scores
Number of subjects: 61
Study: 35327700

Group type: EXPERIMENTAL
Intervention: Dental storybook intervention
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no storybook)
Number of subjects: 88
Study: 32840767

Group type: EXPERIMENTAL
Intervention: Local application of 2.0 g TXA in 10 mL 0.9% NaCl after suturing the joint capsule
Number of subjects: 72

Group type: COMPARATOR
Intervention: Intravenous infusion of 2 g TXA in 200 mL 0.9% NaCl 30 min before the operation
Number of subjects: 72
Study: 34705157

Group type: EXPERIMENTAL
Intervention: Face-to-face instruction and personalized bowel preparation regimens
Number of subjects: 320

Group type: COMPARATOR
Intervention: Routine bowel preparation regimen and education
Number of subjects: 320
Study: 33879260

Group type: EXPERIMENTAL
Intervention: Telemedicine-based medication treatment for opioid use disorder (MOUD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telemedicine-based MOUD
Number of subjects: 0
Study: 32227624

Group type: EXPERIMENTAL
Intervention: Mindfulness session (n = 42)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (n = 26)
Number of subjects: 68
Study: 34998253

Group type: EXPERIMENTAL
Intervention: Emotional Training
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Neutral Training
Number of subjects: 42

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 42
Study: 33093222

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 2924

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 2924
Study: 35947945

Group type: EXPERIMENTAL
Intervention: Linear low-intensity extracorporeal shockwave therapy (LI-LiESWT) using the PiezoWave2 device with a linear shockwave applicator, administered over 4 treatments in a 4-week period.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham group (control group).
Number of subjects: 32
Study: 34642416

Group type: EXPERIMENTAL
Intervention: Green Therapy room
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Virtual Reality room
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control room
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Biophilic interventions
Number of subjects: 33
Study: 32986459

Group type: COMPARATOR
Intervention: 0 mg methamphetamine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 20 mg methamphetamine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 40 mg methamphetamine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 32000474

Group type: EXPERIMENTAL
Intervention: Psychological strategy (walking through the operating room and playfully demonstrating anesthesia equipment)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Midazolam (medication)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Medication (Midazolam)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Psychological strategy
Number of subjects: 43
Study: 34800178

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks plus axitinib 5 mg twice daily
Number of subjects: 94

Group type: COMPARATOR
Intervention: Sunitinib 50 mg once daily (4 weeks on/2 weeks off)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Pembrolizumab-axitinib
Number of subjects: 94

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 94
Study: 32152869

Group type: EXPERIMENTAL
Intervention: BGF MDI 320/18/9.6 μg
Number of subjects: 432
Study: 36344929

Group type: EXPERIMENTAL
Intervention: Polyclonal rabbit antithymocyte globulin (Grafalon®) 6 mg/kg/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Polyclonal rabbit antithymocyte globulin (Grafalon®)
Number of subjects: 80
Study: 34106239

Group type: EXPERIMENTAL
Intervention: Shamiri intervention
Number of subjects: 413

Group type: COMPARATOR
Intervention: Study skills control
Number of subjects: 413
Study: 32562173

Group type: EXPERIMENTAL
Intervention: RJ markers (RJMs) designed from transposable elements’ repeat junctions
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 10 polymorphic RJ primers
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: UPGMA cluster analysis
Number of subjects: 32
Study: 35160211

Group type: EXPERIMENTAL
Intervention: Craniosacral therapy group (CTG)
Number of subjects: 50
Study: 34273367

Group type: COMPARATOR
Intervention: MSFWs working in conventional fields
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: MSFWs working in organic fields
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: MSFWs (overall)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: MSFWs
Number of subjects: 101
Study: 34257012

Group type: EXPERIMENTAL
Intervention: Inhalation of low-dose sevoflurane (end-expiratory concentration, 0.4%) through a face mask
Number of subjects: 336

Group type: COMPARATOR
Intervention: Intranasal ketamine (2 mg/kg)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Inhalation of low-dose sevoflurane
Number of subjects: 336
Study: 32888791

Group type: EXPERIMENTAL
Intervention: Questionnaire responses from research nurses
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with research nurses
Number of subjects: 10
Study: 36210291

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33787576

Group type: EXPERIMENTAL
Intervention: 1-minute CPR training cycles
Number of subjects: 62

Group type: COMPARATOR
Intervention: 2-minute CPR training cycles (Control Group)
Number of subjects: 62
Study: 32507152

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (35 Hz)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham group (sub-therapeutic WBV 8 Hz)
Number of subjects: 12
Study: 36123817

Group type: EXPERIMENTAL
Intervention: Urgent care clinic model
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (traditional ambulatory rotation)
Number of subjects: 59
Study: 32672998

Group type: COMPARATOR
Intervention: Withholding a PD diagnosis
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Disclosing a PD diagnosis (Borderline, Antisocial, Mild, Moderate, Severe)
Number of subjects: 328
Study: 32163578

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment (systolic BP target <120 mmHg)
Number of subjects: 9334

Group type: COMPARATOR
Intervention: Standard blood pressure treatment (systolic BP target <140 mmHg)
Number of subjects: 9334
Study: 36048290

Group type: EXPERIMENTAL
Intervention: Economic strengthening intervention
Number of subjects: 613

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 613
Study: 33148103

Group type: EXPERIMENTAL
Intervention: 20 mg escitalopram
Number of subjects: 64
Study: 32846626

Group type: EXPERIMENTAL
Intervention: Heat‐killed cells of Lactobacillus rhamnosus and Lactococcus lactis
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Heat‐killed cells of Saccharomyces cerevisiae
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of LAB and yeast cells
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Yeast cells alone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no addition of LAB or yeast cells)
Number of subjects: 24
Study: 35634888

Group type: EXPERIMENTAL
Intervention: Home cardiac rehabilitation (home-CR)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Traditional cardiac rehabilitation (TCR)
Number of subjects: 49
Study: 32482150

Group type: EXPERIMENTAL
Intervention: Short-acting beta2 agonists (SABAs)
Number of subjects: 603000000

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory reliever therapy (combination of low dose ICS/fast action bronchodilator)
Number of subjects: 603000000
Study: 32434151

Group type: EXPERIMENTAL
Intervention: Yi Jin Jing exercise
Number of subjects: 30
Study: 36459172

Group type: EXPERIMENTAL
Intervention: Cervical stabilization exercises (progressive home-based program)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 39
Study: 32868662

Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan (Sac/Val)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Conventional angiotensin-converting enzyme inhibitors (ACEI)
Number of subjects: 186
Study: 36451452

Group type: EXPERIMENTAL
Intervention: Esketamine combined with sufentanil (Group H)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Esketamine combined with sufentanil (Group M)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Esketamine combined with sufentanil (Group L)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Esketamine combined with sufentanil (Group H, Group M, Group L)
Number of subjects: 160
Study: 33951140

Group type: EXPERIMENTAL
Intervention: Computer-assisted individualized hemodynamic management
Number of subjects: 38

Group type: COMPARATOR
Intervention: Manually adjusted goal-directed therapy
Number of subjects: 38
Study: 32213306

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 2845

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 2845

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 2845

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 2845

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 2845
Study: 35723774

Group type: EXPERIMENTAL
Intervention: Active remote-microphone listening device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inactive remote-microphone listening device (placebo)
Number of subjects: 0
Study: 33461966

Group type: EXPERIMENTAL
Intervention: iHOT‐33
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EQ‐5D Visual Analogue Scale (VAS)
Number of subjects: 0
Study: 32541380

Group type: EXPERIMENTAL
Intervention: Fluoxetine plus 5-hydroxytryptophan (100 mg twice daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fluoxetine plus placebo
Number of subjects: 60
Study: 36238973

Group type: EXPERIMENTAL
Intervention: Nifedipine (n = 45)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (n = 44)
Number of subjects: 89
Study: 33201771

Group type: EXPERIMENTAL
Intervention: Eravacycline 1 mg/kg intravenously every 12 hours
Number of subjects: 846

Group type: COMPARATOR
Intervention: Carbapenem comparators (ertapenem 1 g intravenously every 24 hours or meropenem 1 g intravenously every eight hours)
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Eravacycline
Number of subjects: 846

Group type: COMPARATOR
Intervention: Carbapenem comparators
Number of subjects: 846

Group type: COMPARATOR
Intervention: Eravacycline and Carbapenem comparators
Number of subjects: 846
Study: 36294062

Group type: EXPERIMENTAL
Intervention: Prism Adaptation + Neck Vibration (Group A)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Neck Vibration only (Group B)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Prism Adaptation only (Group C)
Number of subjects: 36

Group type: COMPARATOR
Intervention: All groups (PA + NV, NV only, PA only)
Number of subjects: 36
Study: 32369844

Group type: EXPERIMENTAL
Intervention: Tertiary prophylaxis with FVIII levels at 1 IU/dL
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Tertiary prophylaxis with FVIII levels between 1 and 10 IU/dL
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Tertiary prophylaxis with FVIII levels of approximately 1 to 3 IU/dL
Number of subjects: 63
Study: 34598883

Group type: EXPERIMENTAL
Intervention: Low-Dose-Rate (LDR) brachytherapy
Number of subjects: 816

Group type: COMPARATOR
Intervention: High-Dose-Rate (HDR) brachytherapy
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Both LDR and HDR brachytherapy
Number of subjects: 816
Study: 35925503

Group type: EXPERIMENTAL
Intervention: TEP technique
Number of subjects: 300

Group type: COMPARATOR
Intervention: TIPP technique
Number of subjects: 300